What is Joseph H. Capper’s total Anika Therapeutics share ownership after this grant?

After the RSU grant, Joseph H. Capper directly holds 30,805 shares of Anika Therapeutics common stock. This figure includes the newly awarded 10,402 RSUs, which will convert into shares when they vest according to the disclosed 2027 vesting schedule.

Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.

Anika Therapeutics director Joseph H. Capper received an equity grant of 10,402 shares of common stock in the form of restricted stock units (RSUs). The award was made on June 18, 2026 at no cash cost to him and increased his direct holdings to 30,805 shares.

Each RSU represents a contingent right to receive one share of Anika Therapeutics common stock. The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027, aligning the director’s compensation with future company performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Capper Joseph H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,402	$0.00	--

Holdings After Transaction: Common Stock — 30,805 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 10,402 shares Total holdings after grant: 30,805 shares Grant price per share: $0.00 per share +2 more

5 metrics

RSU grant size 10,402 shares Restricted stock units awarded on June 18, 2026

Total holdings after grant 30,805 shares Director’s direct ownership following RSU award

Grant price per share $0.00 per share Equity compensation, not a cash market purchase

Vesting date trigger Earlier of 2027 annual meeting or June 18, 2027 RSUs vest in full at this time

Transaction code Code A Grant, award, or other acquisition of common stock

Key Terms

restricted stock units ("RSUs"), contingent right, vest in full, annual meeting of the Company's stockholders

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Company's common stock"

vest in full financial

"The RSUs vest in full on the earlier of the 2027 annual meeting"

annual meeting of the Company's stockholders financial

"on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:30 PM Accepted by SEC EDGAR 06/23/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Capper Joseph H

(Last)

(First)

(Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD

MASSACHUSETTS

01730

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2026		A		10,402⁽¹⁾	A	$0	30,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

	/s/ Joseph H. Capper	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did the Anika Therapeutics (ANIK) Form 4 report for Joseph H. Capper?

The Form 4 reports that director Joseph H. Capper received a grant of 10,402 restricted stock units in Anika Therapeutics common stock. This equity award increased his direct holdings to 30,805 shares following the transaction, aligning part of his compensation with future company performance.

How many Anika Therapeutics RSUs were granted to director Joseph H. Capper?

Joseph H. Capper was granted 10,402 restricted stock units of Anika Therapeutics common stock. Each RSU represents a contingent right to receive one share, providing stock-based compensation that vests over time instead of an immediate cash payment or open-market share purchase.

When do Joseph H. Capper’s Anika Therapeutics RSUs vest?

The RSUs granted to Joseph H. Capper vest in full on the earlier of Anika Therapeutics’ 2027 annual stockholder meeting or June 18, 2027. Vesting means the restricted units convert into common shares, subject to the grant’s continued service and other conditions.

Did Joseph H. Capper buy or sell Anika Therapeutics shares in the market?

The transaction was a grant of 10,402 restricted stock units, not an open-market buy or sale. The Form 4 classifies it as a grant or award acquisition, with a price per share of $0.00, reflecting stock-based compensation rather than a cash transaction.